Control of HBV infection in HIV/HBV co-infected patients treated with antiretroviral therapy – experience of Lodz Centre

Ewelina Wlazłowska; Anna Piekarska; Juliusz Kamerys; Kamila Wójcik-Cichy; Elżbieta Jabłonowska

doi:10.5114/ceh.2022.114160

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 8

Send email

Copy url:

abstract:

Original paper

Control of HBV infection in HIV/HBV co-infected patients treated with antiretroviral therapy – experience of Lodz Centre

Ewelina Wlazłowska

¹

,

Anna Piekarska

¹

,

Juliusz Kamerys

¹

,

Kamila Wójcik-Cichy

¹

,

Elżbieta Jabłonowska

¹

Clinic of Infectious Diseases and Hepatology, Medical University of Lodz, Poland

Clin Exp HEPATOL 2022; 8, 1: 1–6

DOI: https://doi.org/10.5114/ceh.2022.114160

Online publish date: 2022/03/23

View full text Get citation

PlumX metrics:

Aim of the study
To analyse the impact of combined antiretroviral therapy (cART) on selected markers of hepatitis B virus (HBV) infection, as well as assessment of the degree of fibrosis in antiretroviral patients who had HIV/HBV co-infection.

Material and methods
Analysis of HBs antigen (HBsAg), anti-HBs, HBsAg levels, anti-HDV, anti-HCV, as well as assessment of HBV DNA viraemia and liver fibrosis by elastography in people with HIV/HBV co-infection.

Results
Among 515 people under the care of the Lodz Centre at the time of treatment initiation 28 people (5.4%) HBsAg was detected. In HIV/HBV coinfected patients 14 people (50%) had anti-HCV and 6 (21.6%) had anti-HDV. In the group of 23 people treated with antiretroviral therapy for more than 12 months, all but one patient achieved HBV viraemia below the detection threshold. Six (26.1%) eliminated HBsAg, 3 (13%) produced anti-HBs. In the group we examined, four patients has fibrosis at level F4 on the Metavir scale – 3 patients were treated for more than 12 months and one patient was treated for less than 12 months.

Conclusions
Antiretroviral treatment of patients co-infected with HIV/HBV based on tenofovir (in the form of disoproxil or alafenamide) with emtricitabine or lamivudine leads to virological control of HBV infection.

keywords:

Control of HBV infection in HIV/HBV co-infected patients treated with antiretroviral therapy – experience of Lodz Centre

Ewelina Wlazłowska 1 , Anna Piekarska 1 , Juliusz Kamerys 1 , Kamila Wójcik-Cichy 1 , Elżbieta Jabłonowska 1

HIV, HBV, HIV/HBV co-infection, quantitative HBsAg

Ewelina Wlazłowska

¹

,

Anna Piekarska

¹

,

Juliusz Kamerys

¹

,

Kamila Wójcik-Cichy

¹

,

Elżbieta Jabłonowska

¹